New therapies for sickle cell disease

Hematology/Oncology Clinics of North America

Volumn 19, Issue 5, 2005, Pages 975-987

  Okpala, Iheanyi E ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,2 BIS(4 FLUOROPHENYL) 2 PHENYLACETAMIDE; ANTIFUNGAL AGENT; ARGININE; BETA 2 MICROGLOBULIN; CLOTRIMAZOLE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DOCOSAHEXAENOIC ACID; ENZYME INHIBITOR; HEMOGLOBIN F; HEMOGLOBIN S; HYDROXYUREA; ICOSAPENTAENOIC ACID; IMIDAZOLE; IRON; IRON CHELATING AGENT; OMEGA 3 FATTY ACID; OXYGEN; RIBONUCLEOTIDE REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ARTHRALGIA; CARCINOGENESIS; CLINICAL TRIAL; COGNITIVE DEFECT; CYTOPENIA; DIARRHEA; DOSE RESPONSE; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEMOGLOBINOPATHY; HUMAN; LIVER TOXICITY; NAUSEA; NEPHROTOXICITY; OXYGEN BREATHING; PATHOLOGY; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RASH; REVIEW; SICKLE CELL; SICKLE CELL ANEMIA; SICKLE CELL TRAIT; SIDE EFFECT; STROKE; TERATOGENICITY; THALASSEMIA; THROMBOGENICITY; URINE LEVEL; VOMITING; ZINC DEFICIENCY;

ACETAMIDES; ANEMIA, SICKLE CELL; CALCIUM CHANNEL BLOCKERS; CELL ADHESION; CEREBROVASCULAR ACCIDENT; FATTY ACIDS, OMEGA-3; HUMANS; HYDROXYUREA; HYPERTENSION, PULMONARY; IRON OVERLOAD; TRITYL COMPOUNDS;

EID: 26444514376     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2005.08.004     Document Type: Review

References (77)

1. F.I.D. Konotey-Ahulu Hereditary qualitative and quantitative erythrocyte defects in Ghana: an historical and geographical survey Ghana Med J 7 1968 118 119
2. J.A.B. Horton The diseases of tropical climates and their treatment 1874 Churchill London
3. J.B. Herrick Peculiar elongated and sickled red blood corpuscles in a case of severe anaemia Arch Intern Med 6 1910 517 521
4. M.H. Steinberg, and G.P. Rodgers Pathophysiology of sickle cell disease: role of genetic and cellular modifiers Semin Hematol 38 2001 229 306
5. N. Win, T. Yeghen, and M. Needs Use of intravenous immunoglobulin and intravenous methylprednisolone in hyperhaemolysis syndrome in sickle cell disease Hematology 19 2004 433 436
6. P.S. Frenette Sickle cell vaso-occlusion: multistep and multicellular paradigm Curr Opin Hematol 9 2002 101 106
7. I. Okpala The intriguing contribution of white blood cells to sickle cell disease-a red cell disorder Blood Rev 18 2004 65 73
8. H.A. Pearson The kidney, hepatobiliary system, and spleen in sickle cell anaemia Ann NY Acad Sci 565 1989 120 125
9. R.B. Johnston Jr, S.L. Hewman, and A.C. Struth An abnormality of the alternative pathway of complement activation in sickle cell disease N Engl J Med 288 1973 803 805
10. C.C. Anyaegbu, I.E. Okpala, and A.Y. Aken'Ova Complement haemolytic activity, circulating immune complexes and the morbidity of sickle cell anaemia Acta Pathol Microbiol Scand 107 1999 699 702
11. E. Mollapour, J.B. Porter, and R. Kacmarski Raised neutrophil phospholipase A2 activity and defective priming of NADPH oxidase and phospholipase A2 in sickle cell disease Blood 91 1998 3423 3429
12. C.C. Anyaegbu, I.E. Okpala, and A.Y. Aken'Ova Peripheral blood neutrophil count and candidacidal activity correlate with the clinical severity of sickle cell anaemia Eur J Haematol 60 1998 267 268
13. S. Charache, M.L. Terrin, and R.D. Moore Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia N Engl J Med 332 1995 1317 1322
14. M.H. Steinberg Management of sickle cell disease N Engl J Med 340 1999 1021 1030
15. A.G. Shaper, and P. Lewis Genetic neutropenia in people of African ancestry Lancet 2 1971 1021
16. B.J. Bain Ethnic and sex differences in the total and differential white cell count and platelet count J Clin Pathol 49 1996 664 666
17. E.M. Essien Platelets and platelet disorders in Africa (review) Baillieres Clin Haematol 5 1992 441 456
18. O.S. Platt, D.J. Brambilla, and W.F. Rosse Mortality in sickle cell disease-life expectancy and risk factors for early death N Engl J Med 330 1994 1639 1643
19. K. Ohene-Frempong, S.J. Weiner, and L.A. Sleeper Cerebrovascular accidents in sickle cell disease: rates and risk factors Blood 91 1998 288 294
20. T.R. Kinney, L.A. Sleeper, and W.C. Wang Silent cerebral infarcts in sickle cell anemia: a risk factor analysis Paediatrics 103 1999 640 645
21. O. Castro, D.J. Brambilla, and B. Thorington The acute chest syndrome of sickle cell disease: incidence and risk factors in the cooperative study of sickle cell disease Blood 84 1994 643 649
22. M. Abboud, J. Laver, and C.A. Blau Granulocytosis causing sickle cell crisis Lancet 351 1998 959
23. M.H. Steinberg, F. Barton, and O. Castro Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia JAMA 289 2003 1645 1651
24. O. Diav-Citrin, L. Hunnisett, and G.D. Sher Hydroxyurea use in pregnancy: a case report in sickle cell disease and review of the literature Am J Hematol 60 1999 148 150
25. D.C. Byrd, S.R. Pitts, and C.K. Alexander Hydroxyurea in two pregnant women with sickle cell anemia Pharmacotherapy 19 1999 1459 1462
26. L.R. De Pass, and E.V. Weaver Comparison of teratogenic effects of aspirin and hydroxyurea in Fischer 344 and Wistar strains J Toxicol Environ Health 10 1982 297 305
27. I.E. Okpala Assessment of severity and hydroxyurea therapy in sickle cell disease I. Okpala Practical management of haemoglobinopathies 2004 Blackwell Publishing Oxford (UK) 162 168
28. T.R. Kinney, R.W. Helms, and E.E. O'Branski Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phaseI/II trial Blood 94 1999 1550 1554
29. National Institutes of Health (USA) Fetal hemoglobin induction Management of sickle cell disease 4th edition 2002 National Institutes of Health Bethesda (MD) 161 165
30. P. Triadou, M. Maier-Redelsperger, and R. Krishnamoorty Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease Nouv Rev Fr Hematol 36 1994 367 372
31. A.H. Al Jam'a, I.A. Al Dabbous, and A.A. Al Khatti Are we underestimating the leukemogenic risk of hydroxyurea? Saudi Med J 23 2002 1411 1413
32. S. Wilson Acute leukaemia in a patient with sickle cell anemia treated with hydroxyurea Ann Intern Med 133 2000 925 926
33. A. Rauch, M. Borromeo, and A. Ghafoor Leukaemogenesis of hydroxyurea in the treatment of sickle cell anemia Blood 94 1999 415
34. S.M. Bakanay, E. Dainer, and B. Clair Mortality in sickle cell patients on hydroxyurea therapy Blood 105 2005 545 547
35. V.N. Hanft, S.R. Fruchtman, and C.V. Pickens Acquired DNA mutations associated with in vivo hydroxyurea exposure Blood 95 2000 3589 3593
36. S. Charache Mechanisms of action of hydroxyurea in sickle cell anaemia in adults Semin Hematol 34 1997 15 21
37. V.P. Cokic, R.D. Smith, and B.B. Beleslin-Cokic Hydroxyurea induces fetal hemoglobin by nitric-oxide dependent activation of soluble guanylyl cyclase J Clin Invest 111 2003 231 239
38. I.E. Okpala, Y. Daniel, and R. Haynes Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells Eur J Haematol 69 2002 135 144
39. L.A. Styles, B. Lubin, and E. Vichinsky Decrease of very late activation antigen-4 and CD36 expression on reticulocytes in sickle cell patients treated with hydroxyurea Blood 89 1997 2554 2559
40. G.F. Atweh, M. Sutton, and I. Nassif Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease Blood 93 1999 1790 1797
41. Y. Saunthararajah, C.A. Hillery, and D. Lavelle Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic diffrentiation in patients with sickle cell disease Blood 102 2003 3865 3870
42. A. Tomer, S. Kasey, and W.E. Connor Reduction of pain episodes and thrombotic activity in sickle cell disease by dietary n-3 fatty acids Thromb Haemost 85 2001 966 974
43. K. Ghebremeskel, L. Burns, and K. Costeloe Plasma vitamins A and E in preterm babies fed on breast milk or formula milk with or without long-chain polyunsaturated fatty acids Int J Nutr Res 69 1999 83 91
44. M.A. Crawford, I. Golfetto, and K. Ghereeskel The potential role for arachidonic and docosahexanoic acids in protection against some central nervous system injuries in preterm infants Lipids 38 2003 303 315
45. M.A. Crawford, M. Bloom, and L. Broadhurst Evidence for the function of DHA during the evolution of the modern hominid brain Lipids 34 1999 S39 S47
46. K. Ghebremeskel, Y. Min, and B. Thomas The role of essential fatty acids and anti-oxidants in neuro-vascular development and complications of prematurity A. Kujak Textbook of perinatal medicine 2nd edition 2005 Paphenon Publishers New York
47. H. Ren, O. Ibegbulam, and I. Okpala Steady state haemoglobin level in sickle cell anaemia increases with the proportion of erythrocyte membrane n-3 fatty acids Prostaglandins Leukot Essent Fatty Acids 72 6 2005 415 421
48. H. Ren, I. Okpala, and K. Ghebremeskel Blood mononuclear cells and platelets have abnormal fatty acid composition in homozygous sickle cell disease Ann Hematol 84 9 2005 578 583 [Epub 2005 Apr 5]
49. I. Okpala, H. Ren, and O. Ibegbulam Steady state haemoglobin level in sickle cell anaemia increases with the proportion of erythrocyte membrane n-3 fatty acids Blood 104 Suppl 2004 970a
50. J.J. Van den Berg, N.J. de Fouw, and F.A. Kuypers Increased n-3 polyunsaturated fatty acid content of red blood cells from fish oil-fed rabbits increases in vitro lipid peroxidation, but decreases hemolysis Free Radic Biol 11 1991 393 399
51. P.C. Calder N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic Lipids 38 2003 343 352
52. V.L. Marcheselli, S. Hong, and W.J. Lukiw Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression J Biochem (Tokyo) 278 2003 43807 43817
53. B. Khalfoun, G. Thibault, and P. Bardos Docosahexaenoic and eicosapentanoic acids inhibit in vitro human lymphocyte-endothelial cell adhesion Transplantation 62 1996 1649 1657
54. M.L. Burr, A.M. Fehily, and J.F. Gilbert Effects of changes in fat, fish and fibre intakes on death and myocardial infarction: diet and re-infarction trial (DART) Lancet 2 1989 757 761
55. P. Geusens, C. Wouters, and J. Nijs Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. a 12-month, double-blind, controlled study Arthritis Rheum 37 1994 824 829
56. A. Belluzi, C. Bringola, and M. Campieri Effect of enteric-coated fish-oil preparation on relapses in Crohn's disease N Engl J Med 334 1996 1557 1560
57. + transport and reverses erythrocyte dehydration in transgenic SAD mice: a model for therapy of sickle cell disease J Clin Invest 93 1994 1670 1676
58. J.W. Stocker, L. De Franceschi, and G.A. McNaughton-Smith ICA-17043 a novel Gardos channel blocker, prevents sickle red blood cell dehydration in vitro and in vivo in SAD mice Blood 101 2003 2412 2418
59. K.I. Ataga, L.M. DeCastro, and P. Swerdlow Efficacy and safety of the Gardos channel inhibitor, ICA-17043, in paients with sickle cell anemia Blood 104 Suppl 2004 33a
60. A.B. Attah The pathophysiology of sickle cell disease A.F. Fleming Sickle cell disease: a handbook for the general clinician 1982 Churchill Livingstone Edinburgh (Scotland) 43 56
61. D.K. Kaul, M.E. Fabry, and R.L. Nagel The pathophysiology of vascular obstruction in the sickle syndromes Blood Rev 10 1996 29 44
62. D.K. Kaul, H.M. Tsai, and X.D. Liu Monoclonal antibodies to αVβ3 (7E3 and LM609) inhibit sickle red blood cell-endothelial interactions induced by platelet-activating factor Blood 95 2000 368 374
63. A. Gray, E.N. Anionwu, and S.C. Davies Patterns of mortality in sickle cell disease in the UK J Clin Pathol 44 1994 459 463
64. I. Okpala Pulmonary hypertension: a complication of haemolytic states I. Okpala Practical management of haemoglobinopathies 2004 Blackwell Publishing Oxford (UK) 130 133
65. O. Castro Systemic fat embolism and pulmonary hypertension in sickle cell disease Hematol Oncol Clin North Am 10 1996 1289 1303
66. W. Coles, J.S. Nicolas, and P.K. Smatlak A clinical study of the efficacy of nitric oxide delivery via portable versus conventional systems to reduce secondary pulmonary hypertension in sickle cell anemia Abstracts from the National Sickle Cell Conference of USA (Washington [DC], September 17-23, 2002) 2002 Sickle Cell Disease Association of America Washington (DC) 54
67. C.R. Morris, W. Hagar, and J. vam Warmerdam Arginine therapy improves pulmonary artery pressures in patients with sickle cell disease and pulmonary hypertension Blood 100 Suppl 2002 452a
68. A. El-Beshlawy, E. Abdelaouff, and I. Bebawy Pulmonary hypertension in sickle cell disease Abstracts from the 25th Meeting of the International Society of Haematology-African & European Division (Durban [South Africa], September 18-23, 1999) 1999 International Society of Haematology Durban (South Africa) 120
69. R.J. Adams, V.C. McKie, and L. Hsu Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography N Engl J Med 339 1998 5 11
70. J. Kwiatkowiski, and K. Ohene-Frempong Stroke in sickle cell disease I. Okpala Practical management of haemoglobinopathies 2004 Blackwell Publishing Oxford (UK) 134 144
71. K. Ohene-Frempong Indications for red cell transfusion in sickle cell disease Semin Hematol 38 Suppl 1 2001 5 13
72. M.R. DeBaun, R. Mckinstry, and D. White Epidemiology and treatment of silent cerebral infarcts in sickle cell anemia Education program book from the 46th Annual Meeting of American Society of Hematology (San Diego [CA], December 4-7, 2004) 2004 American Society of Hematology Washington (DC) 35 40
73. A.V. Hoffbrand, A. Cohen, and C. Hershko Role of deferiprone in chelation therapy for transfusional iron overload Blood 102 2003 17 22
74. L.J. Anderson, B. Wonke, and E. Prescott Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron levels and ventricular function in beta thalassaemia Lancet 360 2002 516 520
75. A.R. Cohen, R. Galanello, and A. Piga Safety profile of the oral iron chelator deferiprone: a multicenter study Br J Haematol 108 2002 305 312
76. R. Galanello, A. Piga, and D. Alberti Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassaemia J Clin Pharmacol 43 2003 565 572
77. A. Piga, R. Galanello, and M.D. Cappellini Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics and pharmacodynamics after 6 months of therapy Blood 100 Suppl 2002 5a